New gene therapy duo targets hard-to-treat melanoma

NCT ID NCT01397708

Completed Disease control Sponsor: Alaunos Therapeutics Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tested a new approach for people with advanced melanoma (stage III or IV) that cannot be removed by surgery. Participants received injections of a gene therapy directly into their tumors, plus an oral activator drug, to boost the immune system's ability to fight cancer. The main goal was to check safety and tolerability, with 26 adults enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Atlantic Melanoma Center

Morristown, New Jersey, 07960, United States
Fletcher Allen Health

Burlington, Vermont, 05401, United States
Indiana University Health Goshen Center for Cancer Care

Goshen, Indiana, 46526, United States
James Graham Brown Cancer Center

Louisville, Kentucky, 40202, United States
Mary Crowley Cancer Research Center

Dallas, Texas, 75201, United States
Oncology Specialists

Park Ridge, Illinois, 60068, United States
St. Lukes

Easton, Pennsylvania, 15232, United States
The Angeles Clinic

Los Angeles, California, 90404, United States
Washington University

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA